SANOFI PASTEUR
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Subsidiary
- Established
- 1990-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.sanofipasteur.com
DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese Infants
Phase 3
Completed
- Conditions
- DiphtheriaTetanusBacterial MeningitisPoliomyelitisPertussis
- Interventions
- Biological: DTaP-IPV vaccine and Hib vaccineBiological: DTaP-IPV/Hib Combined vaccine
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 424
- Registration Number
- NCT02274285
Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in Adults
Phase 4
Completed
- Conditions
- Influenza
- Interventions
- Biological: Fluzone High Dose vaccine, 2014-2015 formulationBiological: Fluzone® Quadrivalent vaccine, 2014-2015 formulationBiological: Fluzone I®ntradermal vaccine, 2014-2015 formulation
- First Posted Date
- 2014-10-07
- Last Posted Date
- 2015-10-19
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 208
- Registration Number
- NCT02258334
Study of a Single Dose or Two Doses of a Trivalent Inactivated Influenza Vaccine Produced at Shenzhen, China
Phase 4
Completed
- Conditions
- Influenza
- Interventions
- Biological: Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation
- First Posted Date
- 2014-08-29
- Last Posted Date
- 2016-01-29
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 602
- Registration Number
- NCT02228980
Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine
Phase 4
Completed
- Conditions
- Influenza
- Interventions
- Biological: Fluzone® Quadrivalent Influenza Vaccine, No Preservative
- First Posted Date
- 2014-08-21
- Last Posted Date
- 2015-10-19
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 60
- Registration Number
- NCT02222870
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
Phase 2
Completed
- Conditions
- MeningitisMeningococcal MeningitisMeningococcal Infections
- Interventions
- Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate VaccineBiological: Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine
- First Posted Date
- 2014-07-24
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 1715
- Registration Number
- NCT02199691
DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants
Phase 3
Completed
- Conditions
- DiphtheriaTetanusHepatitis BHaemophilus Influenzae Type b InfectionPertussisPoliomyelitis
- Interventions
- Biological: DTaP-IPV-Hep B-PRP~T combined vaccineBiological: DTaP-IPV//PRP~T and Hepatitis B vaccine
- First Posted Date
- 2014-03-24
- Last Posted Date
- 2017-04-26
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 310
- Registration Number
- NCT02094833
Study of SP306 Given Intramuscularly Compared to DT Given Subcutaneously in Japanese Adolescents 11 - 12 Years Old
Phase 3
Completed
- Conditions
- DiphtheriaTetanusPertussis
- Interventions
- Biological: Diphtheria and Tetanus toxoids adsorbed
- First Posted Date
- 2014-03-17
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 534
- Registration Number
- NCT02089347
Study of Tetanus and Diphtheria Toxoids Adsorbed Combined With Component Pertussis Vaccine and Inactivated Poliomyelitis
Phase 2
Completed
- Conditions
- DiphtheriaTetanusPoliomyelitisHepatitis BPertussis
- Interventions
- Biological: Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and IPVBiological: Hepatitis B vaccine
- First Posted Date
- 2014-01-20
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 277
- Registration Number
- NCT02040636
Study of the Immunogenicity and Safety of a Challenge Dose of HBVAXPRO in Healthy Children Vaccinated 10 Years Ago With 3 Doses of HEXAVAC or INFANRIX HEXA
Phase 3
Completed
- Conditions
- Hepatitis BVirus Diseases
- Interventions
- Biological: HBVAXPRO 5µg
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 751
- Registration Number
- NCT02012998
- Locations
- 🇮🇹
Sanofi Pasteur MSD Investigational Site 004, Bologna, Italy
🇮🇹Sanofi Pasteur MSD Investigational Site 009, Cagliari, Italy
🇮🇹Sanofi Pasteur MSD Investigational Site 005, Capannori, Italy
Safety of Two Doses of Avaxim® 80U Pediatric (Inactivated Hepatitis A Vaccine) in Toddlers, Children and Adolescents
Phase 4
Completed
- Conditions
- Hepatitis AHepatitis A Virus
- First Posted Date
- 2013-12-13
- Last Posted Date
- 2015-10-01
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 355
- Registration Number
- NCT02011763
© Copyright 2025. All Rights Reserved by MedPath